2. CONSIDERATIONS FOR VACCINE SAFETY COMMUNICATION
2.1. Audiences and aims of vaccine safety communication.
2.2. Communicating evidence and uncertainties for informed decision-making.
2.3. Transparency for honest communication and public trust-building
Example 2.3: Re-building trust in the MMR vaccine in the United Kingdom
2.4. Perceptions of risk as a trigger of vaccine hesitancy.
Example 2.4.1: Overcoming hesitancy against the MMR vaccine in sub-populations in Sweden.
Example 2.4.2: The need for understanding public concerns over HPV vaccines prior to licensure and launch.
3. PRODUCT LIFE-CYCLE MANAGEMENT APPROACH TO VACCINE SAFETY AND COMMUNICATION
3.1. Communication as part of vaccine pharmacovigilance.
3.2. Pre-licensure and launch phase.
Example 3.2.1: The need for understanding concerns in different communities over the Ebola virus and vaccines prior to launching clinical trials.
Example 3.2.2: Risk management planning for DTPw-HBV quadrivalent vaccine
Example 3.2.3: The introduction of pentavalent vaccines in Kerala, India, supported by close interactions with the healthcare community and the media.
3.3. Post-licensure phase.
Example 3.3.1: Addressing the risk of febrile seizures with a serogroup B meningococcal vaccines in the UK
Example 3.3.2: Addressing the safety concern of narcolepsy for the H1N1 pandemic influenza vaccine used in Sweden
4. VACCINE SAFETY COMMUNICATION PLANS (VacSCPS)
4.1. Application of a strategic communication approach to vaccine safety
Checklist 4.1: Management considerations for VacSCPs
4.2. Developing VacSCPs on the basis of a model template
Template for strategic vaccine type- and situation-specific vaccine safety communication plans (VacSCPs)
4.3. Monitoring, evaluating and maintaining VacSCPs
Monitoring of debates and sentiments in communities and the public
Example 4.3.1: Social media monitoring during polio supplementary immunization activities (SIA) in Israel
Example 4.3.2: Utility of online news media monitoring for prepared communicating of the outcome of a safety assessment for HPV vaccines at the European Medicines Agency (EMA)
5. VACCINE SAFETY COMMUNICATION SYSTEMS
5.1. Functions of vaccine safety communication systems.
Checklist 5.1: Key functions of vaccine safety communication systems
5.2. Multistakeholder network
Checklist 5.2: Establishing and maintaining national stakeholder networks.
Example 5.2: Managing an adverse event following immunization with HPV vaccine in the United Kingdom
5.3. Regional and international awareness and collaboration.
6. CAPACITY BUILDING FOR VACCINE SAFETY COMMUNICATION SYSTEMS
6.1. Skills and capacity requirements
Checklist 6.1: Skills and capacity requirements for vaccine safety communication
6.2. Contents and objectives of training
Example 6.2.1: Training programme on vaccine safety communication by the WHO Regional Office for Europe
Example 6.2.2: Training resources of the Network for Education and Support in Immunisation (NESI)
6.3. Comprehensive approach to capacity building